We are analyzing https://link.springer.com/article/10.1007/s13555-024-01233-w.

Title:
Biomarkers in Cutaneous Keratinocyte Carcinomas | Dermatology and Therapy
Description:
Skin cancer is the most common cancer type in the USA, with over five million annually treated cases and one in five Americans predicted to develop the disease by the age of 70. Skin cancer can be classified as melanoma or non-melanoma (NMSC), the latter including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC). Development of BCC and SCC is impacted by environmental, behavioral, and genetic risk factors and the incidence is on the rise, with the associated number of deaths surpassing those caused by melanoma, according to recent reports. Substantial morbidity is related to both BCC and SCC, including disfigurement, loss of function, and chronic pain, driving high treatment costs, and representing a heavy financial burden to patients and healthcare systems worldwide. Clinical presentations of BCC and SCC can be diverse, sometimes carrying considerable phenotypic similarities to benign lesions, and underscoring the need for the development of disease-specific biomarkers. Skin biomarker profiling plays an important role in deeper disease understanding, as well as in guiding clinical diagnosis and patient management, prompting the use of both invasive and non-invasive tools to evaluate specific biomarkers. In this work, we review the known and emerging biomarkers of BCC and SCC, with a focus on molecular and histologic biomarkers relevant for aspects of patient management, including prevention/risk assessments, tumor diagnosis, and therapy selection.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, article, google, scholar, skin, cell, cas, cancer, scc, carcinoma, bcc, patients, dermatol, central, basal, squamous, mutations, biomarkers, cutaneous, expression, advanced, therapy, tumor, treatment, risk, clinical, including, disease, pathway, carcinomas, tumors, gene, acad, development, study, high, metastatic, protein, common, diagnosis, activation, review, nonmelanoma, differentiation, molecular, genes, bccs, profiling, patient, cancers,

Topics {✒️}

egfr/mek/erk/c-jun signaling [73] org/skin-cancer-information/skin-cancer-facts/ org/public/diseases/skin-cancer/types/common medical writing/editorial assistance healthy-appearing sun-exposed skin cutaneous squamous-cell carcinoma increased n-myc stability rna-induced silencing complexes rna-induced silencing complex advanced basal-cell carcinoma extracellular signal-related kinase article download pdf uv-induced dna damage cell–cell adhesion factors double-blind phase 2 trial cutaneous keratinocyte carcinomas median progression-free survival ongoing phase iii trial oral anti-egfr agent squamous cell carcinomas normal sun-exposed skin real-world clinical practice squamous cell carcinoma basal cell carcinomas basal cell carcinoma real-world treatment patterns basal keratinocyte atypia skin cancer-related deaths hsp90-α significantly increased tumour biol shorter recurrence-free survival promotes degradation table 1 molecular biomarkers privacy choices/manage cookies localized skin reactions photo-exposed skin medicare-eligible patients diagnosed ctcf binding motif stratify higher-risk patients single-arm trial full surgical removal basal epidermal layer cell-surface protein atypical basal cells myc box 1 domain histologic biomarkers related skin molecular biomarkers comprehensive clinicopathologic classification–part single-agent wnt974 low public compliance

Questions {❓}

Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?
Gov/study/NCT03703310?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Biomarkers in Cutaneous Keratinocyte Carcinomas
         description:Skin cancer is the most common cancer type in the USA, with over five million annually treated cases and one in five Americans predicted to develop the disease by the age of 70. Skin cancer can be classified as melanoma or non-melanoma (NMSC), the latter including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC). Development of BCC and SCC is impacted by environmental, behavioral, and genetic risk factors and the incidence is on the rise, with the associated number of deaths surpassing those caused by melanoma, according to recent reports. Substantial morbidity is related to both BCC and SCC, including disfigurement, loss of function, and chronic pain, driving high treatment costs, and representing a heavy financial burden to patients and healthcare systems worldwide. Clinical presentations of BCC and SCC can be diverse, sometimes carrying considerable phenotypic similarities to benign lesions, and underscoring the need for the development of disease-specific biomarkers. Skin biomarker profiling plays an important role in deeper disease understanding, as well as in guiding clinical diagnosis and patient management, prompting the use of both invasive and non-invasive tools to evaluate specific biomarkers. In this work, we review the known and emerging biomarkers of BCC and SCC, with a focus on molecular and histologic biomarkers relevant for aspects of patient management, including prevention/risk assessments, tumor diagnosis, and therapy selection.
         datePublished:2024-07-20T00:00:00Z
         dateModified:2024-07-20T00:00:00Z
         pageStart:2039
         pageEnd:2058
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s13555-024-01233-w
         keywords:
            Biomarkers
            Molecular biomarkers
            Histologic biomarkers
            BCC
            SCC
            Tumor molecular profiling
            Keratinocyte carcinomas
            Non-melanoma skin cancer
            Skin cancer
            Internal Medicine
            Dermatology
            Plastic Surgery
            Oral and Maxillofacial Surgery
            Quality of Life Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13555-024-01233-w/MediaObjects/13555_2024_1233_Fig1_HTML.png
         isPartOf:
            name:Dermatology and Therapy
            issn:
               2190-9172
               2193-8210
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Erica Montano
               url:http://orcid.org/0009-0003-5035-0746
               affiliation:
                     name:DermTech, Inc.
                     address:
                        name:DermTech, Inc., San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Neal Bhatia
               url:http://orcid.org/0000-0001-7448-7809
               affiliation:
                     name:Therapeutics Clinical Research
                     address:
                        name:Therapeutics Clinical Research, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jelena Ostojić
               url:http://orcid.org/0000-0002-8625-8146
               affiliation:
                     name:DermTech, Inc.
                     address:
                        name:DermTech, Inc., San Diego, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Biomarkers in Cutaneous Keratinocyte Carcinomas
      description:Skin cancer is the most common cancer type in the USA, with over five million annually treated cases and one in five Americans predicted to develop the disease by the age of 70. Skin cancer can be classified as melanoma or non-melanoma (NMSC), the latter including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC). Development of BCC and SCC is impacted by environmental, behavioral, and genetic risk factors and the incidence is on the rise, with the associated number of deaths surpassing those caused by melanoma, according to recent reports. Substantial morbidity is related to both BCC and SCC, including disfigurement, loss of function, and chronic pain, driving high treatment costs, and representing a heavy financial burden to patients and healthcare systems worldwide. Clinical presentations of BCC and SCC can be diverse, sometimes carrying considerable phenotypic similarities to benign lesions, and underscoring the need for the development of disease-specific biomarkers. Skin biomarker profiling plays an important role in deeper disease understanding, as well as in guiding clinical diagnosis and patient management, prompting the use of both invasive and non-invasive tools to evaluate specific biomarkers. In this work, we review the known and emerging biomarkers of BCC and SCC, with a focus on molecular and histologic biomarkers relevant for aspects of patient management, including prevention/risk assessments, tumor diagnosis, and therapy selection.
      datePublished:2024-07-20T00:00:00Z
      dateModified:2024-07-20T00:00:00Z
      pageStart:2039
      pageEnd:2058
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s13555-024-01233-w
      keywords:
         Biomarkers
         Molecular biomarkers
         Histologic biomarkers
         BCC
         SCC
         Tumor molecular profiling
         Keratinocyte carcinomas
         Non-melanoma skin cancer
         Skin cancer
         Internal Medicine
         Dermatology
         Plastic Surgery
         Oral and Maxillofacial Surgery
         Quality of Life Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13555-024-01233-w/MediaObjects/13555_2024_1233_Fig1_HTML.png
      isPartOf:
         name:Dermatology and Therapy
         issn:
            2190-9172
            2193-8210
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Erica Montano
            url:http://orcid.org/0009-0003-5035-0746
            affiliation:
                  name:DermTech, Inc.
                  address:
                     name:DermTech, Inc., San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Neal Bhatia
            url:http://orcid.org/0000-0001-7448-7809
            affiliation:
                  name:Therapeutics Clinical Research
                  address:
                     name:Therapeutics Clinical Research, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jelena Ostojić
            url:http://orcid.org/0000-0002-8625-8146
            affiliation:
                  name:DermTech, Inc.
                  address:
                     name:DermTech, Inc., San Diego, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Dermatology and Therapy
      issn:
         2190-9172
         2193-8210
      volumeNumber:14
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:DermTech, Inc.
      address:
         name:DermTech, Inc., San Diego, USA
         type:PostalAddress
      name:Therapeutics Clinical Research
      address:
         name:Therapeutics Clinical Research, San Diego, USA
         type:PostalAddress
      name:DermTech, Inc.
      address:
         name:DermTech, Inc., San Diego, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Erica Montano
      url:http://orcid.org/0009-0003-5035-0746
      affiliation:
            name:DermTech, Inc.
            address:
               name:DermTech, Inc., San Diego, USA
               type:PostalAddress
            type:Organization
      name:Neal Bhatia
      url:http://orcid.org/0000-0001-7448-7809
      affiliation:
            name:Therapeutics Clinical Research
            address:
               name:Therapeutics Clinical Research, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Jelena Ostojić
      url:http://orcid.org/0000-0002-8625-8146
      affiliation:
            name:DermTech, Inc.
            address:
               name:DermTech, Inc., San Diego, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:DermTech, Inc., San Diego, USA
      name:Therapeutics Clinical Research, San Diego, USA
      name:DermTech, Inc., San Diego, USA

External Links {🔗}(608)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.82s.

LINK . SPRINGER . COM {}